In contrast, oestrogen signalling through ERβ produces antitumorigenic cell signalling responses in a broad range of cancers including CRC by repressing ERα transcription and activating antiproliferative cell signalling pathways (Figure 3) [103]. The gene discussed is ESR2; the disease is cancer.